by Jessi O'Connell | Apr 2, 2026 | Insights
If you manage licensing and pharmaceutical compliance for a life sciences or medical device firm, you know the “Sunday Scaries” of the industry: a patchwork of spreadsheets, creeping renewal deadlines, and the constant, low-grade fever of evolving DSCSA...
by Jessi O'Connell | Mar 30, 2026 | Insights
For Contract Manufacturing Organizations (CMOs) and Contract Drug Manufacturing Organizations (CDMOs), licensing has traditionally been viewed as a requirement tied to physical operations. If you manufacture, repackage, or distribute from a specific state, you...
by Jessi O'Connell | Mar 17, 2026 | Insights
The FDA recently finalized a rule that will reshape one of the most widely used identifiers in the pharmaceutical industry: the National Drug Code (NDC). Through its final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” the agency...
by Jessi O'Connell | Mar 6, 2026 | Insights
For compliance specialists across the pharmaceutical and medical device supply chain, the Drug Supply Chain Security Act (DSCSA) has long been viewed as a phased journey. Requirements were introduced incrementally, enforcement timelines shifted, and many organizations...
by Jessi O'Connell | Feb 19, 2026 | Insights
State licensing requirements continue to evolve across the pharmaceutical and medical device landscape. New rules, updated interpretations, revised application forms, and changing renewal timelines can all affect a company’s ability to operate compliantly. For...
by Jessi O'Connell | Feb 11, 2026 | Insights
For pharmaceutical manufacturers, wholesale distributors, 3PLs, repackagers, reverse distributors, and medical device companies, state license renewals are often viewed as routine paperwork. A deadline to track. A form to submit. A fee to pay. But in reality, state...
